

Title (en)  
NANOVESICLES DERIVED FROM BACTERIA OF GENUS ROTHIA, AND USE THEREOF

Title (de)  
NANOVESIKEL AUS BAKTERIEN DER GATTUNG ROTHIA UND DEREN VERWENDUNG

Title (fr)  
NANOVÉSICULES ISSUES DE BACTÉRIES DU GENRE ROTHIA ET LEUR UTILISATION

Publication  
**EP 3926054 A4 20221116 (EN)**

Application  
**EP 20756679 A 20200204**

Priority  
• KR 20190017064 A 20190214  
• KR 20200012637 A 20200203  
• KR 2020001612 W 20200204

Abstract (en)  
[origin: EP3926054A1] The present invention relates to vesicles derived from bacteria of the genus Rothia and a use thereof. The inventors experimentally confirmed that the vesicles significantly decreased in a clinical sample obtained from a patient with diabetes, atrial fibrillation, cardiomyopathy, liver cancer, cirrhosis, dementia, depression, Parkinson's disease, and atopic dermatitis, compared with a normal individual, and when the vesicles isolated from the strain were administered, the secretion of inflammation mediators caused by pathogenic vesicles such as E. coli-derived vesicles was considerably inhibited, and vesicles derived from bacteria of the genus Rothia significantly inhibit cranial nerve cell damage caused by stress hormones, and therefore, the vesicles derived from bacteria of the genus Rothia according to the present invention may be effectively used to develop a method of diagnosing diabetes, atrial fibrillation, cardiomyopathy, liver cancer, cirrhosis, dementia, depression, Parkinson's disease, and atopic dermatitis, and a composition for preventing or treating diabetes, cardiovascular diseases, liver disease, a cranial nerve disease, and an inflammatory disease.

IPC 8 full level  
**C12Q 1/689** (2018.01); **A23L 33/135** (2016.01); **A61K 35/74** (2015.01); **A61P 1/16** (2006.01); **A61P 3/10** (2006.01); **A61P 9/00** (2006.01); **A61P 17/00** (2006.01); **C12Q 1/6883** (2018.01); **C12Q 1/6886** (2018.01)

CPC (source: EP KR)  
**A23L 33/135** (2016.07 - EP KR); **A61K 8/14** (2013.01 - EP); **A61K 8/99** (2013.01 - EP); **A61K 35/74** (2013.01 - EP KR); **A61P 1/16** (2017.12 - EP KR); **A61P 3/10** (2017.12 - EP KR); **A61P 9/00** (2017.12 - EP KR); **A61P 17/00** (2017.12 - EP KR); **A61P 25/16** (2017.12 - KR); **A61Q 7/00** (2013.01 - EP); **A61Q 19/00** (2013.01 - EP); **C12Q 1/6851** (2013.01 - KR); **C12Q 1/6883** (2013.01 - EP KR); **C12Q 1/6886** (2013.01 - EP KR); **C12Q 1/689** (2013.01 - EP KR); **Y02A 50/30** (2017.12 - EP)

Citation (search report)  
• [E] EP 3696284 A1 20200819 - MD HEALTHCARE INC [KR], et al  
• [XP] WO 2019051380 A1 20190314 - EVELO BIOSCIENCES INC [US]  
• [Y] KR 20190003359 A 20190109 - MD HEALTHCARE INC [KR]  
• [Y] KR 101944665 B1 20190201  
• See references of WO 2020166868A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**EP 3926054 A1 20211222; EP 3926054 A4 20221116**; CN 113474470 A 20211001; KR 102285335 B1 20210804; KR 20200099473 A 20200824

DOCDB simple family (application)  
**EP 20756679 A 20200204**; CN 202080014308 A 20200204; KR 20200012637 A 20200203